CLINICAL OUTCOME AFTER LOCAL INJECTION OF ANTIBIOTICS IN DIABETIC FOOT

By

Abd El-Fatah Saleh Abd El-Fatah Abo Zeid Department of General Surgery, Al-Minia University

ABSTRACT:

Objective: To assess outcome of local injection of antibiotic in diabetic foot when systemic antibiotics are not effective.

Patients and methods: Diabetic patients in whom conventional treatment with systemic antibiotic failed with the presence of vascular disease and diabetic foot infections including cellulitis, superficial ulcer, or abscess were included. Areas of cellulitis less than 7.5 cm in diameter usually were injected at one or two sites with 1 ml of antibiotic solution (Gentamycin, 80 mg in 2 ml solution). Larger areas were injected at 2-5 sites with a total of 2 ml of antibiotic solution.

Results: The study included 25 patients, 14 (56%) males and 11 (44%) females, with mean age of 58 ± 7.9 years. The overall number of treated legs was 30. The types of the 30 lesions were: cellulitis in 11 patients (36.7%), abscess in 4 patients (13.3%) and ulcer in 15 patients (50%).

Pain was lessened or relieved in all lesions within a few days of the local injection of antibiotics. The mean follow-up period was 17 ± 3 months. Wound healing was evident and amputation was avoided in 21 of 30 legs (70%) and was not performed after the first 6 months. Three legs (10%) needed amputation. Conversion to another antibiotic after culture done in 6 legs (20%).

Conclusion: When there is a risk of toxicity with systemic antibiotics, the use of local injection of gentamycin in treatment of superficial diabetic ulcer, abscess or cellulitis is safe and effective.

KEYWORDS:

Diabetic foot Infection Ulcer Local antibiotic Genatmycin

INTRODUCTION:

Foot complications are common in diabetic patients¹. Diabetic foot disease is a major health problem, which concerns 15% of the 200 million patients with diabetes worldwide². It is the most important cause of non-traumatic foot amputations^{3,4}.

Gram-positive bacteria, such as Staphylococcus aureus and betahemolytic streptococci, are the most common pathogens in previously untreated mild and moderate infection⁵. Clinically, three distinct stages of diabetic foot infection may be recognized: localized infection, spreading infection and severe infection. Localized infections with limited cellulitis can generally be treated with oral antibiotics on an outpatient basis. Spreading infection should be treated with systemic antibiotics⁶. Topical therapy may be used for some mild superficial infections⁷.

The literature on local antibiotic injection in diabetic foot

infections is scant ^{8,9}. Therefore, in the present study, antibiotics were injected into infected tissue of diabetic foot disease to ensure effective local antibiotic concentrations.

PATIENTS AND METHODS:

The study was conducted at department of general surgery at Minia university hospital from January 2009 to January 2011. Diabetic patients in whom conventional treatment with systemic antibiotic failed with the presence of vascular disease and diabetic foot infections including cellulitis, superficial ulcer, or abscess were included. Foot ulcers that were long standing (>4 weeks), large (>2 cm), and deep (>3 mm) or were associated with a substantially elevated erythrocyte-sedimentation rate (>70 mm/h) were excluded from the study.

Infection was diagnosed clinically, by the presence of systemic signs (e.g., fever, chills, and leukocytosis), purulent secretions (pus), or by local classical signs or symptoms of inflammation (warmth, redness, pain or tenderness, and induration). An ulcer was defined as a break through the full thickness of the dermis¹⁰.

Gentamycin was supplied in vials containing 80 mg of antibiotic in 2 ml solution. Areas of cellulitis less than 7.5 cm in diameter usually were injected at one or two sites with 1 ml of antibiotic solution. Larger areas were injected at 2-5 sites with a total of 2 ml of antibiotic solution. Wound healing was defined as intact skin that

remains intact for at least six months or is intact at the time of death¹⁰.

RESULTS:

The study included 25 patients with mean age of 58 ± 7.9 years. Characteristics of the studied 25 patients with diabetic foot are shown in (Table 1). Of the studied patients, 14 (56%) were males and 11 (44%) were females. Lesions involved one limb in 20 patients (80%) and two limbs in 5 patients (20%), thus the overall number of treated legs was 30. Most of the diabetic patients were on insulin therapy (23;92%). Associated previous medical conditions included: blood pressure > 160/90 despite medication in 8 patients (32%), angina of previous myocardial infarction in 6 patients (24%), congestive heart failure in 5 patients (20%), cerebrovascular disease (stroke or TIA) in 4 patients (16%) and chronic renal failure in 2 patients (8%). The types of the 30 lesions in the studied 25 patients (Table 2) were: cellulitis in 11 patients (36.7%), abscess in 4 patients (13.3%) and ulcer in 15 patients (50%).

Pain was lessened or relieved in all lesions within a few days of the local injection of antibiotics. The mean follow-up period was 17 ± 3 months. Wound healing was evident and amputation was avoided in 21 of 30 legs (70%) and was not performed after the first 6 months. Three legs (10%) needed amputation. Culture was indicated and conversion to another antibiotic rather than gentamycin was done in 6 legs (20%) during the follow-up period (Table 3).

Table 1: Characteristics of 25 patients with diabetic foot.

Characteristics	No. of patients (n=25)	Percentage
Number of treated limbs:		
One limb	20	80%
Two limbs	5	20%
Sex:		
Male	14	56%
Female	11	44%
Treatment of diabetes:		
Insulin	23	92%
Sulfonylurea	2	8%
Smoking habits:		
Active	9	36%
Previous	12	48%
Nonsmokers	4	16%
Associated previous conditions:		
Blood pressure > 160/90 despite medication	8	32%
Angina of previous myocardial infarction	6	24%
Congestive heart failure	5	20%
Cerebrovascular disease (stroke or TIA)	4	16%
Chronic renal failure	2	8%

Table 2: Type of lesions in 30 legs with diabetic foot.

Type of lesion	No. of patients	Percentage
Ulcer	15	50%
Cellulitis	11	36.7%
Abscess	4	13.3%

Table 3: Outcome after treatment of lesions in 30 legs with diabetic foot.

Months from presentation	No. of patients	Percentage
Wound healing	21	70%
Conversion to another treatment	6	20%
Amputation	3	10%

DISCUSSION:

In the present study 70% of diabetic patients, mostly with diabetic foot ulcers (50%) showed complete wound healing after local injection of gentamycin and only 10% of them required amputation within follow-up period 17 ± 3 months.

Foot infections in diabetic patients usually begin in a skin ulceration¹¹. Although most infections remain superficial, 25% will spread contiguously from the skin to deeper subcutaneous tissues and/or bone. About 10%–30% of diabetic patients with a foot ulcer will eventually progress to an amputation, which may be minor (i.e., foot sparing) or major¹².

The studied patients had associated vascular conditions. administration of local antibiotics appears to be especially advantageous in diabetic patients in whom vascular disease and renal failure are commonly found, making nephrotoxic drugs less effective and more dangerous. In the study by Dillon and associates⁸, local therapy was the initial form of therapy for five legs in which standard therapy appeared likely to fail. Infection was controlled in all patients with the use of local antibiotics and compression boot therapy. Early leg amputation was avoided in all but one patient. Late leg amputation occurred in two patients who were lost to follow-up care. Also, little or no gentamycin was found in the serum after the injection of 80 mg in divided doses in various areas of the foot.

The use of gentamycin locally in the management of diabetic foot infections showed an excellent results in treatment of chronic bone and soft tissue infections due to its broad spectrum of action, its bactericidal properties, low rate of primarily

resistant pathogens, and good thermostability 13,14.

The steps to achieving a healthy healing wound include a correct diagnosis, ensuring a good local blood supply, debriding the wound to reveal a clean base, correcting the biomechanical abnormality, and nurturing the wound until it shows signs of healing 15.

In conclusion, the use of local antibiotic injection is safe and effective for treatment and prevention of diabetic foot infections in patients with high risk for the use of systemic antibiotic and had infections rather than oestomylitis. Its advantages over systemic therapy include lower cost, lower risk of toxicity, and tremendously higher concentrations of antibiotics at the desired sites.

REFERENCES:

- 1- Nicolau DP, Stein GE. Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc. 2010;100 (1):52-63.
- 2- Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev. 2006;2(4):431-47.
- 3- Saraogi RK. Diabetic foot ulcer: assessment and management. J Indian Med Assoc. 2008;106(2):112, 114, 116 passim.
- 4- Richard JL, Sotto A, Lavigne JP. New insights in diabetic foot infection. World J Diabetes 2011; 2(2): 24-32.
- 5- Bader MS. Diabetic foot infection. Am Fam Physician. 2008 Jul 1:78(1):71-9.
- 6- Edmonds M. The treatment of diabetic foot infections: focus on ertapenem. Vasc Health Risk Manag. 2009;5:949-63.

- 7- Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS. Infectious Diseases Society of America. Diagnosis and Treatment of Diabetic Foot Infections. Clinical Infectious Diseases 2004; 39:885–910.
- 8- Dillon RS. Successful treatment of osteomyelitis and soft tissue infections in ischemic diabetic legs by local antibiotic injections and the end-diastolic pneumatic compression boot. Ann Surg. 1986;204(6):643-9.
- 9- Dillon RS. Treatment of osteomyelitis in diabetic foot with systemic and locally-injected antibiotics and the end-diastolic pneumatic compression boot Case studies. Vasc Surg (Westerminister Press) 24: 682-695, 1990.
- 10- Larsson J, Agardh CD, Apelqvist J, Stenstrom A. Local signs and symptoms in relation to final amputation level in diabetic patients. A prospective study of 187 patients with

- foot ulcers. Acta Orthop Scand 1994; 65: 387-393.
- 11- Lipsky BA. Infectious problems of the foot in diabetic patients. In: Bowker JH, Pfeifer MA, editors. The diabetic foot. 6th ed. St. Louis: Mosby; 2001, pp: 467-80.
- 12- International Working Group on the Diabetic Foot. International consensus on the diabetic foot, Amsterdam 1999:1-96.
- 13- Klemm K. The use of antibiotic-containing bead chains in the treatment of chronic bone infections. Clin Microbiol Infect. 2001;7:28–31.
- 14- Griffis CD, Metcalfe S, Bowling FL, Boulton AJ, Armstrong DG. The use of gentamycin-impregnated foam in the management of diabetic foot infections: a promising delivery system? Expert Opin Drug Deliv. 2009;6(6):639-42.
- 15- Clemens MW, Attinger CE. Biological basis of diabetic foot wounds. Surg Technol Int. 2008;17:89-95.

النتائج الإكلينيكية لحقن المضادات الحيوية موضعياً في حالات القدم السكري عبد الفتاح صالح عبد الفتاح

-تهدف هذه الدراسة إلى تقييم نتائج حقن المضادات الحيوية موضعياً في حالات القدم السكرية عند وجود موانع لاستخدام المضادات الحيوية وريديا.

المرضى والأدوات:

2009 و يناير 2011، و قد شملت الحالات وجود التهاب خلوي أو تقرحات أو خراج بالقدم، و تم استخدام عقار (جينتاميسين - 80 مجم).

النتائج: شملت الدراسة 25 مريضا بداء السكري، 14 (56%) رجلا و 11 (44%) امرأة، كان متوسط أعمارهم 58 عاما. وقد شملت الإصابات طرف سفلي واحد في 20 مريضا و شملت كلا الطرفين في 5 مرضى ليكون مجموع الأطراف التي تم علاجها هو 30 طرفا. فيما يتعلق بأنواع الإصابات فقد تم علاج 15 مريضاً بتقرحات القدم و 11 مريضا بالالتهاب الخلوي و 4 مرضى بالخراج. و قد لوحظ انخفاض الألم أو اختفاؤه في جميع الحالات بعد أيام قليلة من حقن المضاد الحيوى. خلال فترة متابعة الحالات التي كان متوسطها 17 شهراً تم التئام الجروح و تفادي عمليات البُتر في 21 طرفاً (70%)، إلا أن عمليات البتر أجريت في ثلاثة أطراف (10%)، و كانت هناك حاجة لاستخدام مضاد حيوى آخر بعد إجراء مزرعة بكتيرية في 6 أطراف (20%).

هذه الدراسة تستنتج أن حقن المضاد الحيوي (جينتاميسن) موضعيا آمن و فعال في حالات القدم السكرية التي تشمل الالتهاب الخلوي و القرحة السطحية و الخراج، خاصة عند وجود مخاطر صحية أو احتمال نقص الفاعلية عند استخدام المضادات الحيوية بالحقن الوريدي.